PLX – protalix biotherapeutics, inc. (de) (US:NASDAQ)

News

Protalix BioTherapeutics, Inc. (NYSE: PLX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa [Yahoo! Finance]
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Protalix BioTherapeutics, Inc. (NYSE: PLX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com